Q linea

Q linea EBITDA per Employee

The EBITDA per Employee of Q linea (QLINEA.ST) as of Nov 3, 2026 is -1.32 M SEK. In the previous year, EBITDA per Employee was -1.60 M SEK — a change of -17.34% (higher).

EBITDA per Employee

-1.32 MSEK

YoY

-17.34%

Last updated:

EBITDA per Employee of Q linea is 2025 -1.32 M SEK. EBITDA per Employee of Q linea was 2024 -1.60 M SEK. It decreases by -17.34% higher compared to the previous year.

The Q linea EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-1.02 M SEK
Jan 1, 2019
-1.44 M SEK
Jan 1, 2020
-1.77 M SEK
Jan 1, 2021
-1.81 M SEK
Jan 1, 2022
-2.02 M SEK
Jan 1, 2023
-1.75 M SEK
Jan 1, 2024
-1.60 M SEK
Jan 1, 2025
-1.32 M SEK
The Q linea EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.32 MSEK-17.34%
-1.60 MSEK-8.29%
-1.75 MSEK-13.72%
-2.02 MSEK+11.62%
-1.81 MSEK+2.18%
-1.77 MSEK+22.97%
-1.44 MSEK+41.01%
-1.02 MSEK+88.75%
-542,270.49SEK+10.11%
-492,491.80SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

EBITDA per Employee of Q linea is -1.32 M SEK in 2025.

EBITDA per Employee of Q linea changed from -1.60 M SEK to -1.32 M SEK, representing a -17.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Q linea since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Q linea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Q linea

All Key Metrics — Q linea